Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458549 · ClinicalTrials.gov registry record · NA
Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery
A NA study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 232
- Enrollment target
NCT00458549 is a NA study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 232 participants.
The verdict
NCT00458549, a NA study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 232 participants
- Enrollment target
Study Summary
RATIONALE: Polyunsaturated fatty acids are important for normal growth and development. One type, called omega-3 fatty acids (found in fish, fish oil, and some other foods), may affect the growth of prostate cancer. PURPOSE: This randomized clinical trial is studying polyunsaturated fatty acids in treating patients with prostate cancer undergoing prostate biopsy and/or surgery.
Interventions
- PROCEDURE biopsy
- DIETARY_SUPPLEMENT omega-3 fatty acids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2003-05-27 |
| Est. Completion | 2012-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00458549
The ClinicalTrials.gov registry entry for NCT00458549 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which biopsy is the first listed.
NCT00458549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00458549 about?
NCT00458549 is a clinical study titled "Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery". RATIONALE: Polyunsaturated fatty acids are important for normal growth and development. One type, called omega-3 fatty acids (found in fish, fish oil, and some other foods), may affect the growth of prostate cancer. PURPOSE: This randomized clinical trial is studying polyunsaturated fatty acids in ...
What is the current status of trial NCT00458549?
This trial is currently terminated. It is a NA study. The enrollment target is 232 participants. The study started on 2003-05-27. Estimated completion is 2012-05-01.
What interventions are being tested in trial NCT00458549?
The interventions under investigation include: biopsy (PROCEDURE), omega-3 fatty acids (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00458549?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.